To gain insights into the prognostic role of pretreatment albumin serum levels, we analyzed 429 patients with aggressive B‐cell lymphoma treated with six or eight cycles of CHOP‐14 and eight applications of rituximab from the prospective, multicenter RICOVER‐60 trial [16] with respect to outcome following stratification of patients based on their serum albumin level. Here, ALB is linked to B-cell non-Hodgkin lymphoma.